Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.17 USD 1.27%
Market Cap: 525.8m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Cash from Financing Activities
$252m
CAGR 3-Years
15%
CAGR 5-Years
287%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Cash from Financing Activities
CA$137m
CAGR 3-Years
-48%
CAGR 5-Years
-52%
CAGR 10-Years
19%
Sundial Growers Inc
NASDAQ:SNDL
Cash from Financing Activities
-CA$43.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash from Financing Activities
-$1.1m
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Cash from Financing Activities
-CA$53.9m
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Cash from Financing Activities
-$22.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
525.8m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
2.21 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Cash from Financing Activities?
Cash from Financing Activities
252m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Cash from Financing Activities amounts to 252m USD.

What is Mind Medicine (MindMed) Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
287%

Over the last year, the Cash from Financing Activities growth was 1 181%. The average annual Cash from Financing Activities growth rates for Mind Medicine (MindMed) Inc have been 15% over the past three years , 287% over the past five years .

Back to Top